TY  - GEN
AU  - Cahn,A
AU  - Hamblin,J N
AU  - Begg,M
AU  - Wilson,R
AU  - Dunsire,L
AU  - Sriskantharajah,S
AU  - Montembault,M
AU  - Leemereise,C N
AU  - Galinanes-Garcia,L
AU  - Watz,H
AU  - Kirsten,A M
AU  - Fuhr,R
AU  - Hessel,E M
TI  - Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD
SN  - 1522-9629
PY  - 2018///0612
KW  - Administration, Inhalation
KW  - Aged
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - antagonists & inhibitors
KW  - Cytokines
KW  - metabolism
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Female
KW  - Forced Expiratory Volume
KW  - Humans
KW  - Indazoles
KW  - administration & dosage
KW  - Indoles
KW  - Male
KW  - Middle Aged
KW  - Oxazoles
KW  - Piperazines
KW  - Pulmonary Disease, Chronic Obstructive
KW  - drug therapy
KW  - Severity of Illness Index
KW  - Sputum
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/j.pupt.2017.08.008
ER  -